Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Exosome Diagnostics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is handled by 1 distinct examiner, which indicates a singular point of contact within the patent office. The prosecution is situated in 1 distinct art unit, suggesting a focused technical application for the current filing.
POHNERT, STEVEN C serves as the busiest examiner for the company, with 1 pending office action currently under review. This count of 1 matches the total pending office actions for the portfolio, meaning no other examiners are currently active. For the applicant, this concentration means that the success of the current intellectual property strategy is tied to the specific requirements of this one examiner. Practitioners must focus on the particular examination style and art unit trends associated with this single active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17532363 | URINE BIOMARKERS | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17532363 | URINE BIOMARKERS | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17532363 | URINE BIOMARKERS | POHNERT, STEVEN C | 1683 | §101§103§112DP | Final Rejection | — | Pending | Nov 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExosome Diagnostics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Steven C Pohnert has the most, with 1 of Exosome Diagnostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
